Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell therapy being studied for conditions such as stiff person syndrome, myasthenia gravis, and other autoimmune diseases. The company also has earlier-stage candidates: KYV-102, an autologous CD19 CAR T-cell product with a rapid manufacturing process, and KYV-201, an allogeneic (off-the-shelf) CD19 CAR T-cell product. Additionally, Kyverna has a license and collaboration agreement with Intellia Therapeutics to research and develop an allogeneic CD19-directed CAR cell therapy. The company was originally founded as BAIT Therapeutics in 2018 and rebranded to Kyverna Therapeutics in October 2019.

Kyverna Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol KYTX. Its shares are traded in U.S. dollars (USD). The company is headquartered in Emeryville, California, and operates primarily in the United States. As a Nasdaq-listed company, it is subject to U.S. securities regulations and reporting requirements.

Kyverna Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on developing innovative cell therapies, particularly CAR T-cell treatments, for autoimmune diseases. The biotechnology industry involves using living organisms or their components to create therapeutic products, and Kyverna's work with CAR T-cell therapy represents a cutting-edge approach to treating conditions where the immune system attacks the body's own tissues.

Kyverna Therapeutics is headquartered in Emeryville, California, United States. The company was incorporated in 2018 under the name BAIT Therapeutics, Inc. and rebranded to Kyverna Therapeutics in October 2019. Its focus is on developing cell therapies for autoimmune diseases, with its lead candidate KYV-101 targeting conditions like stiff person syndrome and myasthenia gravis. The company's location in the San Francisco Bay Area places it within a major biotechnology hub, providing access to talent and research collaborations.

Kyverna Therapeutics' lead product candidate is KYV-101, an autologous CD19 CAR T-cell therapy designed to treat autoimmune diseases such as stiff person syndrome and myasthenia gravis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product that features a whole blood rapid manufacturing process, potentially reducing production time. Additionally, Kyverna is working on KYV-201, an allogeneic (donor-derived) CD19 CAR T-cell product candidate that could be used off-the-shelf without needing to be customized for each patient. Furthermore, through a collaboration with Intellia Therapeutics, Kyverna is researching an allogeneic CD19-directed CAR cell therapy, leveraging Intellia's gene-editing expertise.